CGA
EXAS

Crescent Grove Advisors’s Exact Sciences EXAS Stock Holding History

Crescent Grove Advisors’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,005
Closed -$1.63M – 314
2025
Q4 		$1.63M Hold
16,005
– – 0.15% 96
2025
Q3 		$876K Buy
16,005
+2,500
+19% +$125K 0.08% 128
2025
Q2 		$718K Sell
13,505
-500
-4% -$25.4K 0.07% 140
2025
Q1 		$606K Sell
14,005
-190
-1% -$9.62K 0.06% 143
2024
Q4 		$798K Buy
14,195
+150
+1% +$9.34K 0.08% 123
2024
Q3 		$957K Buy
14,045
+500
+4% +$28.2K 0.1% 116
2024
Q2 		$572K Buy
13,545
+2,218
+20% +$122K 0.06% 153
2024
Q1 		$782K Buy
11,327
+300
+3% +$19K 0.08% 135
2023
Q4 		$816K Buy
11,027
+517
+5% +$33.9K 0.09% 128
2023
Q3 		$717K Hold
10,510
– – 0.09% 133
2023
Q2 		$987K Sell
10,510
-520
-5% -$40.6K 0.11% 115
2023
Q1 		$748K Sell
11,030
-140
-1% -$9K 0.09% 132
2022
Q4 		$553K Sell
11,170
-545
-5% -$22.3K 0.06% 167
2022
Q3 		$381K Buy
11,715
+1,538
+15% +$63.4K 0.04% 178
2022
Q2 		$401K Buy
10,177
+5,377
+112% +$288K 0.04% 178
2022
Q1 		$336K Hold
4,800
– – 0.03% 217
2021
Q4 		$374K Hold
4,800
– – 0.04% 206
2021
Q3 		$458K Sell
4,800
-639
-12% -$67.5K 0.05% 165
2021
Q2 		$676K Buy
5,439
+689
+15% +$82.2K 0.07% 131
2021
Q1 		$626K Buy
4,750
+490
+12% +$67.1K 0.07% 119
2020
Q4 		$564K Hold
4,260
– – 0.07% 105
2020
Q3 		$434K Hold
4,260
– – 0.09% 111
2020
Q2 		$370K Hold
4,260
– – 0.08% 108
2020
Q1 		$247K Buy
4,260
+10
+0.2% +$812 0.05% 112
2019
Q4 		$393K Sell
4,250
-500
-11% -$44K 0.07% 108
2019
Q3 		$429K Buy
4,750
+500
+12% +$57K 0.08% 94
2019
Q2 		$502K Hold
4,250
– – 0.09% 88
2019
Q1 		$368K Hold
4,250
– – 0.08% 103
2018
Q4 		$268K Hold
4,250
– – 0.06% 128
2018
Q3 		$335K Hold
4,250
– – 0.07% 100
2018
Q2 		$254K Buy
+4,250
New +$229K 0.06% 116
2018
Q1 		– Sell
-4,250
Closed -$223K – 149
2017
Q4 		$223K Hold
4,250
– – 0.06% 123
2017
Q3 		$200K Buy
+4,250
New +$171K 0.05% 128

Other funds holding EXAS

VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
PWMAG
Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.46B AUM 22.77% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return
BC
Broadwater Capital Boston, Massachusetts $138M AUM 28.86% 1-Year Est. Return

Crescent Grove Advisors's EXAS Position: Q1 2026 in Review

Crescent Grove Advisors sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 16,005 shares — an estimated $1.63M sold.

Crescent Grove Advisors first reported a position in EXAS in Q3 2017 and held it in 33 quarters. The position peaked at $1.63M in Q4 2025. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Crescent Grove Advisors reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Crescent Grove Advisors sold 16,005 Exact Sciences shares in Q1 2026, an estimated $1.63M.
  • Crescent Grove Advisors first reported a position in Exact Sciences in Q3 2017 and held it in 33 quarters.
  • Crescent Grove Advisors's Exact Sciences position peaked at $1.63M in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Crescent Grove Advisors's 13F filing for Q1 2026, filed 6 May 2026.